Other substances

Omeprazole

A benzimidazole proton pump inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

General information

Omeprazole is a selective and irreversible proton pump inhibitor. It is covalently bound to hydrogen-potassium ATPase found on the secretory surface of parietal cells, which inhibits gastric acid secretion (NCIt).

Omeprazole on DrugBank
Omeprazole on PubChem
Omeprazole on Wikipedia

Marketed as

OMEPRAZOLE; ESOMEPRAZOLE SODIUM; Magnesium salt: NEXIUM; OMEPRAZOLE MAGNESIUM; PRILOSEC

 

Structure image - Omeprazole

CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC

Supporting references

Link Tested on Impact factor Notes Publication date
Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2
Small molecule Enzyme assay Screening 		in vitro 6.71

Inhibits SARS-CoV-2 3C-like protease in vitro.

 Jul/28/2020

AI-suggested references

Link Publication date
Potential Effects of Ibuprofen, Remdesivir and Omeprazole on Dexamethasone Metabolism in Control Sprague Dawley Male Rat Liver Microsomes (Drugs Often Used Together Alongside COVID-19 Treatment).
Mar/30/2022
Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal
Nov/25/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04333407 Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. Recruiting Not Applicable Apr/03/2020 Mar/30/2021
  • Alternative id - 20HH5868
  • Interventions - Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Charing Cross Hospital, London, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3170
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate
Export (.csv)